Date: 2016-02-23
Type of information: Resignation
Compound:
Company: Myokardia (USA - CA)
Therapeutic area: Cardiovascular diseases
Type agreement: resignation
Action mechanism:
Disease:
Details: * On February 23, 2016, MyoKardia announced that Jonathan C. Fox, M.D., Ph.D., chief medical officer (CMO), has decided to transition from his current role with MyoKardia by September 30, 2016. At the end of this transition period, he will become an independent, consulting Senior Advisor to the company, lending his expertise to MyoKardia’s ongoing development strategy. MyoKardia is now initiating the process of recruiting Dr. Fox’s successor.
Financial terms:
Latest news:
